| Basics |
Protagonist Therapeutics, Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company with a proprietary peptide-based technology platform focused on discovering and developing new chemical entities to address significant unmet medical needs.
|
| IPO Date: |
August 11, 2016 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$5.6B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.58 | 2.84%
|
| Avg Daily Range (30 D): |
$1.39 | 1.70%
|
| Avg Daily Range (90 D): |
$1.54 | 2.26%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.49M |
| Avg Daily Volume (30 D): |
.66M |
| Avg Daily Volume (90 D): |
.8M |
| Trade Size |
| Avg Trade Size (Sh.): |
72 |
| Avg Trade Size (Sh.) (30 D): |
46 |
| Avg Trade Size (Sh.) (90 D): |
50 |
| Institutional Trades |
| Total Inst.Trades: |
3,041 |
| Avg Inst. Trade: |
$2.99M |
| Avg Inst. Trade (30 D): |
$6.53M |
| Avg Inst. Trade (90 D): |
$5.1M |
| Avg Inst. Trade Volume: |
.1M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$4.35M |
| Avg Closing Trade (30 D): |
$13.89M |
| Avg Closing Trade (90 D): |
$12.3M |
| Avg Closing Volume: |
147.65K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$-.62
|
$-.55
|
|
Diluted EPS
|
|
$-.62
|
$-.55
|
|
Revenue
|
$
|
$ 4.71M
|
$ 5.55M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -39.34M
|
$ -34.77M
|
|
Operating Income / Loss
|
$
|
$ -46.42M
|
$ -42.04M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ -54.83M
|
$ 28.96M
|
|
PE Ratio
|
|
|
|
|
|
|
